Gene Vector Market, By Vector Type (Viral Vectors (Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Gamma-Retroviral Vectors, Herpes Simplex Viral Vectors, Poxviral/Vaccinia Vectors, Other Viral Vectors and Non-Viral Vectors (Plasmid DNA Vectors, Lipid-Based Nanoparticle Vectors, Polymeric/Synthetic Nanoparticle Vectors, Inorganic Nanoparticle Vectors)), By Payload Type (DNA Vectors, RNA Vectors, siRNA/shRNA Vectors, CRISPR/Cas Components, Antisense Oligonucleotides, and mRNA Vectors), By Application (Gene Replacement Therapy, Gene Addition/Augmentation Therapy, Gene Silencing/Knockdown, Gene Editing, Cell Therapy Manufacturing, Vaccines, and Research Use Only), By Disease Area (Oncology, Neurology, Cardiovascular and Metabolic, Ophthalmic, Hematologic and Immunologic, Infectious Diseases, Musculoskeletal and Genetic Muscle Disorders, Dermatology and Wound Healing, and Other Rare Genetic Disorders), By Delivery Route (Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intratumoral, Ocular, Inhalation, and Others), By Delivery Mode (In Vivo Delivery and Ex Vivo Delivery), By End User (Biopharmaceutical and Biotechnology Companies, CDMOs/CMOs (Contract Development and Manufacturing Organizations), Academic and Research Institutes, Government and Non-Profit Research Organizations, and Hospital-Based and Specialty Gene Therapy Centers), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)